Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality
Reads0
Chats0
TLDR
In this paper, the authors determined the frequency of metastatic (M1) prostate cancer at presentation in different age groups, to examine the association of age with PC-specific mortality, and to calculate the relative contribution of various age groups to the pool of M1 cases and PC deaths.Abstract:
BACKGROUND The objectives of this study were to determine the frequency of metastatic (M1) prostate cancer (PC) at presentation in different age groups, to examine the association of age with PC-specific mortality, and to calculate the relative contribution of different age groups to the pool of M1 cases and PC deaths. METHODS Records from 464,918 patients who were diagnosed with PC from 1998 to 2007 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The patients were categorized according to age into groups ages <50 years, 50 to 54 years, 55 to 59 years, 60 to 64 years, 65 to 69 years, 70 to 74 years, 75 to 79 years, 80 to 84 years, 85 to 89 years, and ≥ 90 years. The cumulative incidence of death from PC was computed using the Gray method. RESULTS The frequency of M1 PC at presentation was 3% for the group aged <75 years, 5% for the group ages 75 to 79 years, 8% for the group ages 80 to 84 years, 13% for the group ages 85 to 89 years, and 17% for the group aged ≥ 90 years. The 5-year cumulative incidence of death from PC was 3% to 4% for all patients with PC in any category aged <75 years, 7% for patients ages 75 to 79 years, 13% for patients ages 80 to 84 years, 20% for patients ages 85 to 89 years, and 30% for patients aged ≥ 90 years. Although patients aged ≥ 75 years at PC diagnosis represented just over a quarter (26%) of all PC cases, they contributed almost half (48%) of all M1 cases and more than half (53%) of all PC deaths. CONCLUSIONS Compared with younger patients (aged <75 years), older patients were more likely to present with very advanced disease, had a greater risk of death from PC despite higher death rates from competing causes, and contributed more than half of all PC deaths. Awareness of this issue may improve future outcomes for elderly patients with PC.read more
Citations
More filters
Journal ArticleDOI
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Karim Fizazi,Nam Phuong Tran,Luis Fein,Nobuaki Matsubara,Alfredo Rodríguez-Antolín,Boris Alekseev,Mustafa Ozguroglu,Dingwei Ye,Susan Feyerabend,Andrew Protheroe,Peter De Porre,Thian Kheoh,Youn C. Park,Mary B. Todd,Kim N. Chi +14 more
TL;DR: The addition of abiraterone acetate and prednisone to androgen‐deprivation therapy significantly increased overall survival and radiographic progression‐free survival in men with newly diagnosed, metastatic, castration‐sensitive prostate cancer.
Journal ArticleDOI
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study
TL;DR: It is concluded that prospective trials are needed to further evaluate the role of LT in mPCa, and local therapy (LT) appeared to confer a survival benefit in this large population-based study.
Journal ArticleDOI
Distribution of metastatic sites in patients with prostate cancer: A population-based analysis
Giorgio Gandaglia,Giorgio Gandaglia,Firas Abdollah,Firas Abdollah,Jonas Schiffmann,Vincent Trudeau,Shahrokh F. Shariat,Simon P. Kim,Paul Perrotte,Francesco Montorsi,Alberto Briganti,Quoc-Dien Trinh,Pierre I. Karakiewicz,Maxine Sun +13 more
TL;DR: The aim of this study was to systematically describe the most common sites of metastases in a contemporary cohort of PCa patients.
Journal ArticleDOI
Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.
TL;DR: In this paper, the authors determined the frequency of metastatic (M1) prostate cancer at presentation in different age groups, to examine the association of age with PC-specific mortality, and to calculate the relative contribution of various age groups to the pool of M1 cases and PC deaths.
Journal ArticleDOI
Bone marrow adipocytes promote the warburg phenotype in metastatic prostate tumors via HIF-1α activation
Jonathan Diedrich,Erandi Rajagurubandara,Mackenzie K. Herroon,Gargi Mahapatra,Maik Hüttemann,Izabela Podgorski +5 more
TL;DR: Using in vitro and in vivo models of marrow adiposity, it is demonstrated that marrow fat cells promote Warburg phenotype in metastatic prostate cancer cells, and evidence that adipocytes drive metabolic reprogramming of tumor cells via oxygen-independent mechanism of Hif-1α activation that can be reversed by HIF-1 α downregulation is provided.